📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 12:45
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Interise Trust Allots Rs 1,736.30 Cr Commercial Papers for 29-Day Tenure
Interise Trust's Investment and Finance Committee has allotted 34,726 unsecured, listed, rated Commercial Papers (CPs) on September 2, 2026. The issue aggregates to Rs 1,736.30 Crores with a face value of Rs 5 Lakhs per paper. The papers have a short tenure of 29 days and are expected to be listed on BSE Limited by September 3, 2026.
Confidence: HIGH
What changedInterise Trust has successfully allotted Rs 1,736.30 Crores of short-term commercial papers.
Why it mattersProvides short-term liquidity management and working capital support for the InvIT, indicating access to short-term money markets.
Total Issue Size: Rs 1,736.30 CroresNumber of CPs Allotted: 34,726Face Value per CP: Rs 5 LakhsTenure: 29 daysExpected Listing Date: September 3, 2026
📅 Short termEnsures liquidity for short-term operational and refinancing needs over the next 29 days.
📈 Long termLimited; routine short-term money market instrument for cash flow management.
⚠ Risk flags
- Refinancing risk upon maturity given the short 29-day tenure
Key Highlights
Total issue size of Rs 1,736.30 Crores across 34,726 Commercial Papers
Face value of Rs 5 Lakhs per Commercial Paper
Maturity tenure of 29 days from allotment date of September 2, 2026
Listing expected on BSE Limited by September 3, 2026
👀 What to Watch
Track the listing on BSE by September 3, 2026, and monitor the trust's refinancing or redemption schedule upon maturity in 29 days.
Interise Trust: Concession Period for Krishnagiri Thopur Toll SPV Concluded on Aug 23, 2026
Interise Trust has announced the conclusion of the concession period for its project SPV, Krishnagiri Thopur Toll Road Private Limited, effective August 23, 2026 at 5:30 PM IST. In accordance with the concession agreement with the National Highways Authority of India (NHAI), toll collection revenues have ended and the project has been handed over to NHAI. The SPV has initiated the handover of remaining project assets and is awaiting the vesting certificate. The project consisted of a 4-lane BOT road section on NH-44 from Krishnagiri to Thumpipadi in Tamil Nadu.
Confidence: HIGH
What changedToll collection and operational control of the Krishnagiri-Thumpipadi BOT project have been formally transferred to NHAI following the scheduled expiry of its concession period.
Why it mattersToll revenues from this specific SPV will cease contributing to Interise Trust's consolidated cash flows, marking the scheduled operational sunset of this underlying road asset.
Concession End Date & Time: August 23, 2026 at 5:30 PM ISTQuarterly Revenue (Jun 2026): Rs 385.359 cr
📅 Short termRoutine administrative transition as toll collections cease and asset handover protocols are completed with NHAI.
📈 Long termPortfolio lifecycle event; InvITs routinely manage concession expiries and rely on fresh asset acquisitions or pipeline additions to offset maturing concessions.
⚠ Risk flags
- Loss of recurring toll revenue from the matured Krishnagiri Thopur SPV
- Any pending hand-back maintenance obligations or claims prior to vesting certificate issuance
Key Highlights
Concession period ended on August 23, 2026 at 5:30 PM IST per the NHAI agreement
Toll collection revenue from the SPV has concluded and operations handed over to NHAI
Project covered the 4-lane expansion of NH-44 between Krishnagiri and Thumpipadi in Tamil Nadu
SPV is currently in the process of obtaining the final vesting certificate from NHAI
👀 What to Watch
Track the impact of the SPV concession expiry on future trust toll revenues and distribution yields in the upcoming quarterly results, alongside the formal receipt of the NHAI vesting certificate.
Interise Trust Approves Commercial Paper Issuance Up to ₹1,800 Crore
Interise Trust announced that the Investment and Finance Committee of its Investment Manager approved the issuance of Commercial Papers (CPs) up to an aggregate limit of ₹1,800 crore in one or more tranches on August 21, 2026. This authorization enables the infrastructure trust to access short-term debt markets for liquidity, working capital, or debt refinancing. For context, the trust reported quarterly revenue of ₹385.36 crore in Q1 FY27 (June 2026).
Confidence: HIGH
What changedThe Investment and Finance Committee authorized a short-term borrowing program via Commercial Papers up to ₹1,800 crore.
Why it mattersProvides Interise Trust with flexible short-term liquidity and lower-cost market borrowing options compared to long-term bank loans, though it introduces rollover requirements.
Max CP issuance limit: ₹1,800 croreJun 2026 quarterly revenue: ₹385.36 croreCP limit vs Q1 revenue: ~4.67x
📅 Short termEnhances the trust's financial flexibility in managing working capital and debt maturity profiles over coming months.
📈 Long termLimited structural impact on equity/unit value unless proceeds are used to fund yield-accretive infrastructure asset acquisitions.
⚠ Risk flags
- Rollover and refinancing risk characteristic of short-term commercial papers
- Interest rate sensitivity on floating or short-tenor debt
Key Highlights
Approved issuance of Commercial Papers up to an aggregate amount not exceeding ₹1,800 crore
Issuance authorized in one or more tranches
Approval granted by the Investment and Finance Committee on August 21, 2026
Approved issuance represents ~4.67x of Q1 June 2026 revenue of ₹385.36 crore
👀 What to Watch
Track subsequent disclosures for individual tranche issuances, coupon rates, tenors, and the specific deployment of proceeds (e.g., debt refinancing vs. new asset funding).
₹2.30 per unit distribution declared by Interise Trust; Record Date Aug 15, 2026
Interise Trust has declared a distribution of ₹2.30 per unit for the quarter ended June 30, 2026. The payout is structured as ₹1.70 in interest, ₹0.20 as return of capital, and ₹0.40 as dividend. The board has fixed August 15, 2026, as the record date, though eligibility will be determined by the beneficiary position at the close of August 14, 2026, due to the national holiday. This distribution follows the approval of the Trust's unaudited standalone and consolidated financial results for Q1 FY27.
Confidence: HIGH
What changedThe Trust has formalized its quarterly distribution amount and established the timeline for payment to unitholders.
Why it mattersFor an Infrastructure Investment Trust (InvIT), regular distributions are the primary source of investor returns; the specific breakdown of the payout affects the net post-tax yield for unitholders.
Total Distribution: ₹2.30 per unitInterest Component: ₹1.70 per unitDividend Component: ₹0.40 per unitReturn of Capital: ₹0.20 per unitRecord Date: August 15, 2026
📅 Short termThe units may see price adjustments as they trade ex-distribution around the record date; liquidity usually remains stable for established InvITs during payout periods.
📈 Long termRegular distributions demonstrate the underlying infrastructure assets' ability to generate consistent cash flows, which is central to the InvIT's long-term investment thesis.
⚠ Risk flags
- Taxation risk on interest component
- Regulatory compliance regarding distribution timelines
Key Highlights
Total distribution declared at ₹2.30 per unit for the quarter ended June 30, 2026
Interest component represents the majority of the payout at ₹1.70 per unit
Record date set for August 15, 2026, with the effective cutoff on August 14, 2026
Dividend component of ₹0.40 per unit is subject to applicable withholding taxes
Return of capital component fixed at ₹0.20 per unit
👀 What to Watch
Investors should verify their holdings by the close of August 14, 2026, to ensure eligibility and consult tax advisors regarding the varying tax treatments of the interest, dividend, and capital return components.
₹2.30 per unit distribution declared by Interise Trust for Q1 FY27
Interise Trust has declared a distribution of ₹2.30 per unit for the quarter ended June 30, 2026. The distribution is composed of three parts: ₹1.70 as interest, ₹0.20 as return of capital, and ₹0.40 as dividend. The board has fixed August 15, 2026, as the record date, though the effective date for determining eligibility is August 14, 2026, due to the national holiday. This announcement follows the approval of the trust's unaudited standalone and consolidated financial results for the first quarter.
Confidence: HIGH
What changedInterise Trust has finalized its quarterly financial results and authorized a cash distribution to its unitholders.
Why it mattersAs an InvIT, regular distributions are the primary return mechanism for investors; this payout confirms the trust's continued cash flow generation from its infrastructure assets.
Total Distribution: ₹2.30 per unitInterest Component: ₹1.70 per unitDividend Component: ₹0.40 per unitReturn of Capital: ₹0.20 per unitRecord Date: August 15, 2026
📅 Short termThe units may see activity leading up to the August 14 record date as investors position themselves for the ₹2.30 per unit payout.
📈 Long termConsistent quarterly distributions are critical for InvIT valuations; investors should monitor if the payout levels are sustained by underlying asset cash flows over future quarters.
⚠ Risk flags
- Taxability of distribution components varies
- Interest rate fluctuations impacting InvIT attractiveness
Key Highlights
Total distribution declared at ₹2.30 per unit for the quarter ended June 30, 2026
Interest component accounts for the largest share at ₹1.70 per unit
Dividend and Return of Capital components are ₹0.40 and ₹0.20 per unit respectively
Record date for distribution eligibility is August 15, 2026 (effective August 14, 2026)
Unaudited standalone and consolidated financial results for Q1 FY27 have been approved
👀 What to Watch
Investors should note the record date of August 14, 2026, to be eligible for the payout and review the tax implications of the different distribution components (interest vs. dividend).
Eris Q1 FY27: 13% Revenue Growth to ₹873 Cr; GLP-1 Market Leadership Established
Eris Lifesciences reported a 13% YoY revenue growth to ₹873 Cr for Q1 FY27, with PAT increasing 14.5% to ₹143 Cr. The Domestic Branded Formulations (DBF) segment grew 14.2% organically, though consolidated EBITDA margins compressed to 34% from 36% YoY due to product mix shifts. A key highlight is the company's leadership in the generic GLP-1 (Semaglutide) market, achieving a #1 rank in prescriptions with a 21% share. The company is currently undergoing EU CAPA actions for Swiss Parenterals, targeting audit readiness by December 2026.
Confidence: HIGH
What changedEris has successfully established market leadership in the new GLP-1 category and significantly increased its insulin market share, transitioning from acquisition integration to organic volume growth.
Why it mattersThe shift towards high-growth biologics and chronic therapies is driving volume, though it is causing temporary margin compression. Success in the EU-CDMO business and Insulin Analogs is critical for the next leg of growth.
Q1 Revenue: ₹873 crQ1 PAT Growth (YoY): 14.5%GLP-1 Prescription Share: 21%Insulin Market Share: 16%Q1 EBITDA Margin: 34%Q1 Capex: ₹88 cr
📅 Short termThe market is likely to view the double-digit PAT growth and GLP-1 leadership positively, though margin compression in the international business may be a point of concern in the coming weeks.
📈 Long termStructural growth is supported by a robust chronic portfolio and a ₹700-800 Cr EU-CDMO order book. Long-term value depends on successful EU site audits and scaling the insulin analog pipeline.
⚠ Risk flags
- Margin contraction in International business
- Regulatory audit risks for Swiss Parenterals sites
- High debt levels (₹2,101 Cr)
Key Highlights
Consolidated Revenue reached ₹873 Cr, up 13% YoY, contributing ~28% to TTM revenue.
Insulin market share (RHI + Glargine) expanded to 16% from 9% at the time of the Biocon acquisition.
Sundae (Semaglutide) achieved #1 rank in generic prescriptions with a 21% share and 20% unit share.
Swiss Parenterals revenue grew 5% to ₹72 Cr, but EBITDA contracted 19% YoY to ₹18 Cr due to EU compliance costs.
Operating Cash Flow (OCF) remained strong at 77% of EBITDA, with Q1 capex of ₹88 Cr.
👀 What to Watch
Monitor the recovery of the OAD and Cardiac segments (35% of portfolio) which are currently lagging market growth. Watch for the completion of EU CAPA actions by Dec-2026 and the planned entry into the ₹2,309 Cr Insulin Analogs market in FY28.
₹3,130 Cr TTM Revenue Base: Eris Lifesciences Approves Q1 FY27 Results with Clean Audit Report
Eris Lifesciences' Board approved the unaudited financial results for the quarter ended June 30, 2026, in a meeting held on July 29, 2026. The statutory auditors, Walker Chandiok & Co LLP, issued an unmodified limited review report, confirming no qualifications in the financial statements. Additionally, the company re-appointed M/s Kiran J. Mehta & Co. as Cost Auditors for FY 2026-27. While specific Q1 P&L figures were not detailed in the cover letter, the company continues to manage a debt of ₹2,101 Cr following recent acquisitions.
Confidence: MEDIUM
What changedFormal approval and regulatory filing of the Q1 FY27 financial results and auditor re-appointment.
Why it mattersEnsures regulatory compliance and provides a clean bill of health regarding accounting practices through an unmodified auditor's report.
TTM Revenue: ₹3,130 CrTotal Debt: ₹2,101 CrDebt-to-Equity Ratio: 0.66Market Capitalization: ₹19,951 Cr
📅 Short termThe stock may see neutral to volatile movement depending on how the specific Q1 growth numbers compare to the 11-15% guidance.
📈 Long termFocus remains on the integration of ₹3,900+ Cr worth of acquisitions and the scale-up of the EU-CDMO business.
⚠ Risk flags
- High debt levels (₹2,101 Cr) relative to net worth.
- Execution risk in integrating large acquisitions like Biocon's domestic business.
Key Highlights
Board meeting conducted over 1.5 hours from 11:30 AM to 1:00 PM on July 29, 2026.
Unmodified audit opinion received for both standalone and consolidated results.
Re-appointment of Cost Auditors for the 2026-27 financial year approved.
Company maintains a TTM revenue base of ₹3,130 Cr as per recent financial context.
👀 What to Watch
Review the full financial tables for organic growth trends and margin expansion in the Biocon domestic business segment.
Eris Lifesciences Reports FY26 Revenue of ₹3,129 Cr with 36% EBITDA Margin
Eris Lifesciences has demonstrated significant growth through a series of leveraged acquisitions, investing over ₹4,300 Cr between FY23 and FY26. The company reported a consolidated revenue of ₹3,129 Cr for FY26, with EBITDA margins expanding by 400 bps to 36% since FY23. Domestic branded formulations remain the core strength, with 80% of revenue coming from super-specialty segments, while the international business has grown to contribute 11% of total revenue. The company now operates 6 globally accredited manufacturing facilities and has expanded its addressable market by 43%.
Key Highlights
Invested over ₹4,300 Cr in strategic acquisitions from FY23 to FY26, including Biocon's injectable and nephro businesses.
FY26 Revenue reached ₹3,129 Cr with an EBITDA of ₹1,120 Cr, achieving a 36% operating margin.
Expanded the Domestic Total Addressable Market (TAM) by 43% to approximately ₹1,17,000 Cr between 2022 and 2026.
Maintains a leading 16% market share in Insulins and a Top-5 position in the Indian Anti-Diabetes therapy market.
International business now spans 70+ countries, contributing 11% to the consolidated revenue in FY26.
👀 What to Watch
Investors should note the successful integration of high-value acquisitions and the resulting margin expansion; the stock remains a strong play on the Indian super-specialty chronic market with growing international exposure.
Eris Lifesciences FY26 DBF EBITDA Hits ₹1,026 Cr; Semaglutide Launch Gains #1 Volume Rank
Eris Lifesciences reported a steady FY26 with Domestic Branded Formulations (DBF) revenue growing 11% YoY to ₹2,778 crore and EBITDA margins expanding to 37%. A major highlight is the successful launch of 'Sundae' (Gx Semaglutide), which achieved the #1 rank in injectable volume and 22% prescription share within its first month. However, the company faced approximately ₹110 crore in revenue losses due to delayed product launches and supply constraints at its Bhopal facility. The international business also faced regulatory headwinds following procedural non-compliance observations from an EU-GMP inspection, delaying the EU-CDMO pipeline.
Key Highlights
FY26 DBF EBITDA grew 12% YoY to ₹1,026 crore with margins improving to 37% from 36.5%.
Insulin segment grew 32%, significantly outperforming the Chronic Value Market (CVM) growth of 6.7%.
Sundae (Semaglutide) brand ranked #1 in injectable volume and #2 in value as of April 2026.
International business revenue grew 7% to ₹348 crore, missing Q4 targets due to supply chain disruptions.
Management guides for FY27 DBF revenue growth at 1.3x of CVM growth with stable 37% margins.
👀 What to Watch
Investors should focus on the scale-up of the high-margin Semaglutide franchise and the resolution of EU-GMP audit observations. While domestic growth remains strong, the international segment's recovery depends on successful remediation and facility re-inspection.
Eris Lifesciences Declares Rs 7.21 Interim Dividend; Sets May 29 as Record Date
Eris Lifesciences has declared an interim dividend of Rs 7.21 per equity share for the financial year 2026-2027, which is a 721% payout on the face value of Re 1. The company has fixed May 29, 2026, as the record date to determine eligibility for this payment. Alongside the dividend, the board approved the audited financial results for the quarter and year ended March 31, 2026, with a clean audit report. Shareholders can expect the dividend disbursement to be completed by June 19, 2026.
Key Highlights
Interim dividend of Rs 7.21 per equity share (721% of face value) declared for FY 2026-27.
Record date for dividend eligibility established as May 29, 2026.
Dividend payment to be processed on or before June 19, 2026.
Audited standalone and consolidated financial results for FY26 approved with unmodified audit opinions.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date to qualify for the Rs 7.21 per share payout. Additionally, shareholders should review the full FY26 earnings report for insights into the company's growth trajectory.
Eris Lifesciences Declares ₹7.21 Interim Dividend and Approves FY26 Audited Results
Eris Lifesciences has approved its audited financial results for the fiscal year ended March 31, 2026. The Board declared an interim dividend of ₹7.21 per equity share, representing a 721% payout on the face value of ₹1. The record date for dividend eligibility is set for May 29, 2026, with the payment to be disbursed by June 19, 2026. The auditors provided an unmodified opinion, ensuring the financial statements are free from material qualifications.
Key Highlights
Interim dividend of ₹7.21 per share (721% of face value) declared for FY 2026-27
Record date for dividend eligibility fixed as May 29, 2026
Audited FY26 financial results approved with an unmodified audit opinion
Dividend payment to be completed on or before June 19, 2026
Board meeting concluded with no reported financial qualifications or irregularities
👀 What to Watch
Investors should ensure they hold the stock before the May 29 record date to qualify for the ₹7.21 dividend. The clean audit report provides confidence in the company's financial transparency.
Eris Lifesciences Subsidiary ETL Assigned and Affirmed 'IND AA' Rating; Outlook Stable
India Ratings has affirmed the 'IND AA/Stable/IND A1+' rating for Eris Therapeutics' INR 4,200 million bank facilities and assigned the same to a new INR 1,000 million limit. The rating reflects parent Eris Lifesciences' strong market position (19th in IPM) and robust consolidated EBITDA margins of approximately 35%. Consolidated net leverage improved significantly from 4.0x in FY24 to 2.2x in FY25, with expectations to drop below 1.5x by FY27. The company's strategic shift toward chronic therapies and injectables via acquisitions like Biocon Biologics is expected to drive long-term growth.
Key Highlights
Ind-Ra affirmed 'IND AA/Stable/IND A1+' rating for INR 4,200 million facilities and assigned it to new INR 1,000 million limits
Consolidated net leverage improved to 2.2x in FY25 from 4.0x in FY24, with a target of below 1.5x by FY27
EBITDA for 9MFY26 reached INR 8.5 billion compared to INR 7.6 billion in 9MFY25
Chronic therapy portfolio accounts for 83% of revenue as of March 2026, significantly higher than the IPM average of 56%
Successful integration of multiple acquisitions including Biocon Biologics and Swiss Parenterals to expand into injectables and insulin
👀 What to Watch
Investors should take confidence in the stable credit rating and the company's ability to reduce leverage following major acquisitions. Monitor the timely refinancing or repayment of INR 12.5 billion in NCDs maturing between December 2026 and June 2027.
India Ratings Affirms Eris Lifesciences' 'IND AA' Rating with Stable Outlook
India Ratings (Ind-Ra) has affirmed Eris Lifesciences' Long-term Issuer Rating at 'IND AA' with a Stable outlook, reflecting its strong position in the Indian pharmaceutical market. The company's EBITDA improved to INR 8.5 billion in 9MFY26, supported by successful integration of acquisitions and a shift toward high-margin chronic therapies. Financial health is improving, with net leverage dropping from 3.9x in FY24 to 2.2x in FY25, and a further reduction to below 1.5x expected by FY27. The company now ranks 19th in the Indian Pharmaceutical Market, up from 22nd in 2022.
Key Highlights
Ind-Ra affirmed 'IND AA/Stable' rating for Long-term Issuer and bank facilities of INR 11,980 million.
EBITDA grew to INR 8.5 billion in 9MFY26 from INR 7.6 billion in 9MFY25, maintaining margins over 35%.
Net leverage (Net Debt/EBITDA) improved significantly to 2.2x in FY25 from 3.9x in FY24.
Chronic and sub-chronic therapies now account for 83% of the portfolio, significantly higher than the IPM average of 56%.
Successful integration of acquisitions like Biocon Biologics' branded formulations has expanded the manufacturing base to six facilities.
👀 What to Watch
The rating affirmation and improving leverage metrics signal a successful deleveraging path following major acquisitions. Investors should maintain a positive outlook as the company scales its high-margin chronic therapy and injectable segments.
Eris Lifesciences Reports Non-Compliance Observations at Swiss Parenterals Units 1 and 2
Eris Lifesciences' subsidiary, Swiss Parenterals, has received non-compliance observations from HALMED (Croatia) following an inspection of its Ahmedabad facilities from March 9th to 13th, 2026. The observations affect Unit 1 (general injectables) and Unit 2 (betalactam injectables) and are procedural in nature, requiring improvements to meet EU GMP standards. While the company expects minimal impact on current business, the commercialization of its EU-CDMO product pipeline will face delays. Eris is currently preparing remediation actions and Corrective and Preventive Actions (CAPA) to seek a follow-on inspection.
Key Highlights
Inspection conducted by HALMED (Croatia) at Swiss Parenterals Units 1 and 2 from March 9 to 13, 2026
Observations pertain to procedural improvements for compliance with EU GMP Directive 2017/1572
Direct impact includes a delay in the commercialization of the EU-CDMO product pipeline
Company states there is minimal impact on existing business operations
Next steps involve executing remediation actions and requesting a follow-on inspection from the agency
👀 What to Watch
Investors should monitor the timeline for CAPA submission and the subsequent follow-up inspection results, as any prolonged delay in the EU-CDMO pipeline could impact long-term growth estimates.
Eris Lifesciences Completes Acquisition of Velbiom Probiotics Business
Eris Lifesciences Limited has officially closed the transaction to acquire the probiotics business of Velbiom Probiotics Private Limited. This follows the initial agreement announced on March 20, 2026, marking a strategic expansion into the high-growth probiotics segment. The completion of this deal allows Eris to integrate specialized products into its existing healthcare portfolio. This move aligns with the company's long-term strategy of inorganic growth through niche therapeutic acquisitions.
Key Highlights
Formal closure of the acquisition of Velbiom Probiotics Private Limited's business.
The transaction was finalized on March 31, 2026, following the March 20 agreement.
Strategic focus on strengthening Eris's presence in the specialty probiotics market.
The acquisition is expected to leverage Eris's existing distribution network for immediate scale.
👀 What to Watch
Investors should monitor the integration of this new business segment and its impact on the company's margins in the upcoming fiscal quarters. The stock remains a positive watch for those focused on specialty pharmaceutical growth.
Eris Lifesciences Partners with Natco Pharma to Launch Generic Semaglutide in March 2026
Eris Lifesciences has entered a strategic partnership with Natco Pharma to commercialize generic Semaglutide in India, a transformative therapy for Type 2 diabetes and weight management. Natco has secured CDSCO approval for manufacturing, with the commercial launch slated for March 2026. This move strengthens Eris's position in the metabolic care segment, leveraging its existing network of 5,00,000+ retail pharmacies and 5,000 stockists. The company has invested approximately INR 4,000 crore over the last three years to diversify its portfolio and scale its chronic therapy presence.
Key Highlights
Strategic partnership with Natco Pharma for the launch of generic Semaglutide under the brand 'Sundae'.
Commercial launch expected in March 2026 following CDSCO manufacturing approval for Natco.
Eris reported FY25 revenue of INR 2,894 crore and has grown operating profit 2.6x over the last 5 years.
The company maintains a strong diabetes franchise with a reach across 5,00,000+ retail pharmacies in India.
Total investment of ~INR 4,000 crore in the last 3 years towards technology and therapeutic diversification.
👀 What to Watch
Investors should monitor the launch execution in March 2026 as Semaglutide represents a high-growth opportunity in the Indian metabolic market. The stock remains a strong play on the chronic therapy segment given its aggressive portfolio expansion and 2.6x profit growth over five years.
Eris Lifesciences to Acquire Velbiom Probiotics Business for Rs 50 Crore
Eris Lifesciences has entered into a Business Transfer Agreement to acquire the branded probiotic portfolio of Velbiom Probiotics Private Limited for Rs 50 crore. The acquisition, executed on a slump sale basis, includes specialized formulations for metabolic health, gut wellness, and women’s health. Velbiom reported revenues of Rs 16.02 crore for the first nine months of FY26, showing steady performance compared to Rs 19.64 crore in FY25. This strategic move allows Eris to deepen its presence in the high-growth microbiome-based therapy and research segment.
Key Highlights
Acquisition of Velbiom Probiotics' branded business for a total cash consideration of Rs 50 crore
Target business revenue stood at Rs 16.02 crore for 9M FY26 and Rs 19.64 crore for FY25
Portfolio focuses on high-growth areas including metabolic health, gut wellness, and women’s health
Transaction structured as a slump sale on a going concern basis with no related party involvement
Acquisition aims to leverage Velbiom's science-driven India-specific microbiome therapy research
👀 What to Watch
This is a positive bolt-on acquisition that strengthens Eris's specialty portfolio; investors should monitor the integration and its contribution to margin expansion in future quarters.
Eris Lifesciences Targets <1.5x Debt-to-EBITDA by Dec 2026; EPS Inflection Point Expected in FY26
Eris Lifesciences is transitioning from a heavy investment cycle to an earnings growth phase, projecting an EPS inflection point starting FY26. The company has invested over INR 4,300 crore in acquisitions since FY23, expanding into high-growth segments like Dermatology, Nephrology, and Insulins. Management expects to reduce Net Debt to TTM EBITDA from 3.9x in FY24 to below 1.5x by December 2026. With EBITDA margins improving to 36% in 9M FY26 and a strong pipeline in GLP-1 and Insulin analogues, the company is positioned for significant scale-up in domestic and international markets.
Key Highlights
Invested INR 4,300+ crore in acquisitions between FY23 and FY26 to diversify into super-specialty segments.
EBITDA margins expanded by 400 bps from 32% in FY23 to 36% in 9M FY26.
Net Debt to TTM EBITDA reduced to 1.6x in Q3 FY26, with a target of <1.5x by Dec 2026.
Insulin market share doubled to 16% post-Biocon acquisition, with a long-term target of 25%.
Planned capex of INR 380-400 crore over the next 2-3 quarters for Diabesity and Injectables.
👀 What to Watch
Investors should monitor the successful integration of the Biocon and Swiss Parenterals acquisitions and the upcoming launch of Semaglutide. The company's focus on debt reduction and margin expansion suggests a favorable outlook for bottom-line growth over the next 2-3 years.
Eris Lifesciences Q3 FY26: Adj. PAT Surges 38.5%, International Business Grows 45%
Eris Lifesciences reported a robust Q3 FY26 with consolidated revenue growing 11% YoY to Rs. 807 crore and adjusted PAT rising 38.5% to Rs. 120 crore. The International Business was a standout performer, growing 45% YoY, while the Domestic Branded Formulations (DBF) segment maintained steady 10% growth. The company is strategically pruning its portfolio by discontinuing low-margin tail-end brands to focus on high-growth therapies like Insulins and GLP-1. Debt reduction remains on track with a target Net Debt/EBITDA ratio of under 1.5x by December 2026.
Key Highlights
Consolidated Q3 Revenue grew 11% YoY to Rs. 807 crore with EBITDA margins improving to 34.9%.
International Business revenue surged 45% YoY to Rs. 111 crore, with FY27 revenue guidance of Rs. 550-600 crore.
RHI Cartridges market share tripled to 25% since the Biocon acquisition, meeting the company's stated strategic objective.
Decision to discontinue non-core tail-end brands will impact FY27 DBF revenue by 2% but improve core margins to ~39%.
Net Debt to TTM EBITDA reduced to 2.1x as of Dec 2025, with a clear path to <1.5x by Dec 2026.
👀 What to Watch
Investors should focus on the company's successful integration of acquisitions and its pivot towards high-margin chronic therapies like Insulins and the upcoming GLP-1 launch. The portfolio rationalization and debt reduction trajectory are positive indicators for long-term value creation.
Eris Lifesciences Q3 FY26 Net Profit Grows 25% YoY to ₹108.8 Cr; Revenue Up 11%
Eris Lifesciences reported a solid performance for Q3 FY26, with consolidated revenue growing 11% YoY to ₹807.45 crore. Net profit for the quarter increased by 25% YoY to ₹108.83 crore, despite an exceptional charge of ₹17.24 crore. On a sequential basis, while revenue grew slightly, net profit saw a decline from ₹134.47 crore in the previous quarter due to higher tax expenses and the exceptional item. The company's debt-to-equity ratio improved to 0.67 from 0.79 YoY, reflecting better leverage management.
Key Highlights
Consolidated Revenue from operations grew 11% YoY to ₹807.45 crore in Q3 FY26.
Net Profit increased 25% YoY to ₹108.83 crore, even after accounting for a ₹17.24 crore exceptional item.
Nine-month (9M FY26) Net Profit stands at ₹368.40 crore, up significantly from ₹273.02 crore in 9M FY25.
Debt-Equity ratio improved to 0.67 from 0.79 in the year-ago period, indicating debt reduction.
Interest Service Coverage Ratio strengthened to 4.33 from 3.04 YoY, showing improved debt servicing capacity.
👀 What to Watch
Investors should view the strong YoY profit growth and improving debt profile as positive indicators of operational efficiency. The sequential dip in profit warrants monitoring of margins and tax impacts in upcoming quarters.
